Home > Boards > US Listed > Biotechs > Autolus Therapeutics plc (AUTL)

The AUTO6NG product consists of three distinct populations

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
jondoeuk Member Profile
 
Followed By 17
Posts 1,258
Boards Moderated 1
Alias Born 10/24/15
160x600 placeholder
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 1/8/2021 4:16:40 PM
Autolus Therapeutics provides business outlook for 2021 & 2022 GlobeNewswire Inc. - 1/6/2021 4:07:15 AM
Autolus Therapeutics to participate in Investor Conferences through January GlobeNewswire Inc. - 1/4/2021 7:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 12/7/2020 4:02:13 PM
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the 62nd ASH Annual Meeting GlobeNewswire Inc. - 12/7/2020 12:01:00 PM
Autolus Therapeutics presents compelling AUTO1 data from ALLCAR Phase 1 study in Adult Acute Lymphoblastic Leukemia (ALL) dur... GlobeNewswire Inc. - 12/5/2020 3:01:00 PM
Autolus Therapeutics announces publication of new AUTO6 Phase 1 data in childhood neuroblastoma in Science Translational Medi... GlobeNewswire Inc. - 11/30/2020 7:00:00 AM
Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in ... GlobeNewswire Inc. - 11/17/2020 7:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/5/2020 4:04:54 PM
Autolus Therapeutics Reports Third Quarter 2020 Financial Results and Operational Progress GlobeNewswire Inc. - 11/5/2020 7:00:00 AM
Autolus Therapeutics to Report Third Quarter 2020 Financial Results and Host Conference Call on November 5 GlobeNewswire Inc. - 10/30/2020 7:00:10 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/18/2020 8:01:56 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/18/2020 7:12:50 AM
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO Virtual Congress 2020 GlobeNewswire Inc. - 9/18/2020 3:05:10 AM
Autolus Therapeutics to host Investor Conference Call to discuss AUTO3 data presented at ESMO and to participate in Banking c... GlobeNewswire Inc. - 9/8/2020 7:00:10 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/27/2020 6:04:02 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 8/13/2020 4:10:04 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/6/2020 4:07:57 PM
Autolus Therapeutics Reports Second Quarter 2020 Financial Results and Operational Progress GlobeNewswire Inc. - 8/6/2020 7:00:10 AM
Autolus announces changes to its Board and Management Team GlobeNewswire Inc. - 8/4/2020 7:00:10 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 8/3/2020 4:13:33 PM
Autolus Therapeutics to Report Second Quarter 2020 Financial Results and Host Conference Call on August 6 GlobeNewswire Inc. - 7/30/2020 7:00:10 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 7/20/2020 4:10:57 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 7/6/2020 4:16:26 PM
Amended Annual and Transition Report (foreign Private Issuer) (20-f/a) Edgar (US Regulatory) - 6/30/2020 4:14:54 PM
jondoeuk   Saturday, 11/16/19 12:57:15 PM
Re: None
Post # of 17 
The AUTO6NG product consists of three distinct populations of GD2-targeted CAR-T cells, produced by dual transduction of T-cells with two separate retroviral vectors. The first vector directs the expression of a GD2-targeting CAR, co-expressed with a constitutively signalling IL7 cytokine receptor (product A), while the second vector is a tri-cistronic retroviral vector encoding the same CAR, co-expressed with dominant negative TGF-b receptor and truncated SHP2 (product B). This yields a mix of product A/B/A+B.

Here is some preclinical data (slides from the least deck)






Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences